GENESIS Pharma, a regional biopharma company specialized in the commercialization of innovative medicines targeting severe and rare diseases in Central and Eastern Europe, announces an exclusive distribution agreement for the cancer medicine cemiplimab in Greece, Cyprus and Malta with Regeneron Ireland DAC. Regeneron Ireland DAC is a wholly owned subsidiary of Regeneron, a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. 
Cemiplimab is an effective PD-1 inhibitor approved by the European Medicines Agency for certain patients with advanced basal cell carcinoma, advanced cutaneous squamous cell carcinoma, advanced non-small cell lung cancer and advanced cervical cancer.

GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor (GIST) in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.
RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Kyowa Kirin and GENESIS Pharma announce new partnership for rare disease medicines portfolio in Greece, Cyprus and Malta
 
December 20, 2022 – Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and GENESIS Pharma, a leading regional biopharma company operating in the broader region of Southeast Europe, have announced a commercialization agreement for two new orphan-designated medicines in Greece, Cyprus and Malta. Under the terms of the agreement, GENESIS Pharma will commercialize Burosumab for the treatment of X-Linked Hypophosphataemia (XLH) and Tumour-Induced Osteomalacia (TIO) and Mogamulizumab for two subtypes of cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin lymphoma, upon local market approval.

GENESIS Pharma Announces Expansion of Commercialization Agreement with Incyte

The expanded agreement includes two new orphan-designated cancer medicines in 11 markets in Southeast Europe   

25 October 2022 –GENESIS Pharma, a leading regional biopharma company operating in the broader region of Southeast Europe, today announced an expansion of the exclusive supply and distribution agreement with Incyte Biosciences International Sàrl, continuing their successful six year collaboration for ponatinib. The expanded agreement includes the commercialization of two new, orphan-designated, cancer medicines as well as the geographical extension of the agreement to include 11 markets: Greece, Cyprus, Croatia, Slovenia, Malta, Serbia, North Macedonia, Bosnia and Herzegovina, Kosovo, Albania and Montenegro.

GENESIS Pharma enters into exclusive agreement with Seagen to commercialize a new cancer therapy for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer

20 October 2021 –GENESIS Pharma, a leading regional biopharma company operating in the broader region of Southeast Europe, announced their exclusive agreement with Seagen Inc, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for the commercialization of an innovative, new cancer medicine in Greece, Cyprus and Malta, to treat patients with HER2 positive locally advanced or metastatic breast cancer.
 

GENESIS Pharma enters into exclusive agreement with Jazz Pharmaceuticals to commercialize a therapy for certain types of High-Risk Acute Myeloid Leukemia in adults (t-AML and AML-MRC) in Greece, Cyprus and Malta.
 
29 September 2021 –GENESIS Pharma, a leading regional biopharma company operating in the broader region of South East Europe, announced their exclusive agreement with Jazz Pharmaceuticals, a global biopharmaceutical company dedicated to developing life-changing medicines for serious diseases, for the commercialization of a cancer medicine in Greece, Cyprus and Malta, for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

fabryfamilytree.gr: A new awareness website for people with Fabry disease diagnosis and their families
 
It includes an easy-to-use family tree builder application that helps in tracking potential family members who may also have a Fabry-related mutation.

Athens, 06.29.2020 – GENESIS Pharma won the Platinum Award for its CSR performance for 2019-2020 in the Greek Corporate Responsibility Index (CR Index) by the Corporate Responsibility Institute. The company also received the "Best Progress Award" demonstrating the greater progress in its category, as an acknowledgment of its growing investment and improving performance in sustainable practices and social contribution activities.

During the CR Index process, independent experts evaluate the CSR performance of the participating companies and their impact on society, the environment, the market and the workplace, based on international standards and criteria. GENESIS Pharma is among the most awarded companies in Greece for its CSR performance, as it was the first pharmaceutical company to participate and be awarded in the index since 2009.

Partnership with GENESIS Pharma marks an important step in the global commercial expansion of patisiran, the first-in-class ‘gene-silencing’ RNAi therapeutic

Under the terms of the agreement, GENESIS Pharma will be responsible for the sales and marketing, medical affairs, regulatory and reimbursement support for migalastat in the above markets.

The company supports her Olympic preparations for the 10km Open Water Finals of the Rio Olympics.

Since 2014, GENESIS Pharma has been supporting the efforts of the Greek marathon swimmer Kelly Araouzou for qualification to the Rio Olympics 2016 as an exclusive sponsor, while today it stands by her in the final stretch before the big finals of the 10km open water swimming to be held on August 15, 2016.
Kelly earned her qualification for the Olympics a year ago, at the 16th FINA World Championships in Kazan where she won the 8th place in the 10km open water swimming. In Kazan she also won a silver medal in the 5km open water swimming, her highest personal achievement to date.
 

For the sixth consecutive year GENESIS Pharma is awarded in the National Corporate Responsibility Index-CR Index, receiving its second Gold award. This long-term presence in the Index as well as the improved scores that the company has achieved over the years signify its strong commitment to corporate responsibility.